Amphista Therapeutics Limited’s Post

Our team recently enjoyed some delicious ice cream from Jack's Gelato, who have partnered with Granta Park, a world-leading science technology and biopharmaceutical park within the vibrant Cambridge biopharma ecosystem and ‘golden triangle’ of London, Oxford and Cambridge where Amphista is based. A big thank you to Jack's Gelato for bringing smiles to our faces and to the newly opened café area, The Clubhouse, for providing a wonderful new space for our community to gather. #JacksGelato #GrantaPark #TeamBuilding #Wimbledon #IceCream #TPD #Biotech #DrugDiscovery

Last week marked Amphista’s Great Big Green Week, dedicated to promoting recycling and environmental awareness through various engaging activities and initiatives. Activities included: ▪️ Promoting recycling and knowledge sharing; ▪️ Distributing seed cards and a biodiversity walk to connect with local nature; ▪️ A day of sustainable travel where individuals were encouraged to car share or bicycle to work; ▪️ ‘Big Switch Off' day to encourage energy conservation in both office and lab; ▪️ And a quiz on environmentally friendly lifestyle changes. #DrugDiscovery #Biotech #TPD

#ICYMI – Last week, Scott Hughes, Director of Exploratory Biology at Amphista, gave a presentation on our new differentiated mechanism of action for #BRD9 at the 5th Virtual Bio-Techne Targeted Protein Degradation and Induced Proximity Symposium. The webinar, which covers new developments from leading scientists working in induced proximity research, provided a great opportunity to share our recently announced data demonstrating that Amphista’s bifunctional degraders induced degradation of BRD9 by target-assisted E3 ligase recruitment. Watch Scott’s presentation here: https://lnkd.in/drq-9THE #DrugDiscovery #Biotech #TPD #TargetedProteinDegradation #InducedProximity

Victoria Lovatt, Vice President of Intellectual Property at Amphista, recently participated as one of five invited lecturers in the World Intellectual Property Organization – WIPO Patent Drafting Training Program held in Geneva, Switzerland. Victoria, who has over 25 years’ experience on all aspects of intellectual property, including patents and trade secrets, shared her experience with attendees to enhance their ability to prepare and file successful patent applications and secure the best protection possible for inventions.   Thank you, WIPO, for inviting Victoria to share her expertise and contribute to the next generation of high-quality patent professionals! #IntellectualProperty #DrugDiscovery #Biotech #TargetedProteinDegradation

This #PrideMonth we celebrated with a fabulous ‘Potluck’ style picnic in the sunshine. It was great to enjoy a couple of hours in the company of our diverse and talented team, and promote inclusivity, allyship, and a safe and welcoming space for each other. We proudly stand in solidarity with the LGBTQ+ community and will continue to champion inclusivity and equality not just during Pride Month, but all year round. #PrideMonth #Inclusivity #Diversity #Equality #AmphistaTherapeutics

Celebrating our annual Company Day in Cambridge last week. We learnt about our colour energies in a personal impact and effectiveness team building session with 'Inspire Ignite’ Coaching & Training, followed by a BBQ and some light-hearted competition in the brilliant ‘Labyrinth’ with BRIGHT VISION EVENTS LTD. Reflecting on our progress in 2024 so far, we’re excited about the future as we continue to develop the next generation of targeted protein degraders! Our progress this year includes: ☑️ Demonstrated in vivo efficacy and CNS activity of our mechanistically differentiated targeted protein degraders ☑️ Unveiled a new differentiated mechanism of action for the degradation of BRD9 #TeamBuilding #People #Amphista #TargetedProteinDegradation #TPD

Watch our Senior Director, Discovery Chemistry, Andrea Testa talk about Amphista’s exciting new differentiated mechanism of action for #BRD9, which he presented at the 2024 Protein Degradation in Focus Symposium.   #Biotech #TPD #TargetedProteinDegradation #DrugDiscovery

June is #Alzheimer’s & Brain Awareness Month. Organised by Alzheimer's Association®, this initiative is an opportunity to raise awareness and discuss Alzheimer’s disease and other dementias. Over 55 million people worldwide are living with Alzheimer’s or other dementias, which remain the only major cause of death without a treatment to prevent, slow or stop disease progression. This prevalence underscores our commitment at Amphista to unlock the full potential of TPD for the treatment of neurodegenerative diseases and to #ENDALZ, using our CNS penetrant, bifunctional protein degrader molecules with leading physicochemical properties. Discover more here: https://lnkd.in/dRjuh-U #Biotech #TPD #DrugDiscovery #AlzheimersAwarenessMonth

ICYMI – Last week, BioCentury Inc. covered Amphista’s unveiling of a new mechanism of action (MOA) for the degradation of BRD9, an emerging target in #oncology, on Wednesday 22 May by our Senior Director, Discovery Chemistry, Dr Andrea Testa. The demonstration of BRD9 degradation in vivo via this MOA, which is completely differentiated from cereblon- or VHL-based PROTACs, marks a significant step forward in the #TPD field. It underscores Amphista’s proprietary chemistry and high-quality science, which we are applying to the discovery and development of additional targeted glues to expand the offering of TPD medicines beyond CRBN and VHL-based agents and bring effective treatments to patients in areas of high unmet need. Read the full piece by Danielle Golovin, Ph.D. here: https://lnkd.in/eftFtfHf #BioCentury #DrugDiscovery #Biotech #TargetedProteinDegradation #CeTPD

We have today announced the unveiling of a new differentiated mechanism of action for the degradation of BRD9, an emerging target in oncology, at the 2024 Protein Degradation in Focus Symposium organised by the University of Dundee. Our Scientific Co-Founder and Senior Director, Discovery Chemistry, Dr Andrea Testa, delivered the exciting news at a presentation titled “Degradation of BRD9 by a novel targeted glue”. He showed that Amphista’s bifunctional degraders selectively induce the proximity of BRD9 to DCAF16, leading to strong and rapid degradation of BRD9. This important discovery builds upon our earlier announcement of two compelling data sets demonstrating in vivo efficacy, and the ability to target and degrade proteins in the central nervous system with our next generation bifunctional degraders. These achievements highlight our proprietary chemistry and high-quality science which we are applying to develop a portfolio of first- and/or best-in-class of degraders with leading physicochemical properties. Read the full announcement here: https://lnkd.in/exa-d_Jt #DrugDiscovery #Biotech #TargetedProteinDegradation #CeTPD #TPD